Monopar enrolls first patient in Phase 1 trial of MNPR-101-Zr radiopharmaceutical

Monopar Therapeutics

First-in-human Phase 1 dosimetry and imaging trial of MNPR-101-Zr, a uPAR-targeting radiopharmaceutical.
Up to 12 patients with advanced cancers will be enrolled in the study.
Trial led by Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre.
First human study of a radiolabeled monoclonal antibody targeting uPAR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.